NBIX Neurocrine Biosciences Inc.

101.59
0  0%
Previous Close 101.59
Open
Price To Book 16.28
Market Cap 9,355,780,798
Shares 92,093,521
Volume 0
Short Ratio
Av. Daily Volume 1,008,931
Stock charts supplied by TradingView

NewsSee all news

  1. Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results

    SAN DIEGO, Jan. 20, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb.

  2. Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

    Xenon's Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of Partnered

  3. Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones

    SAN DIEGO, Jan. 12, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today provided an update on its business performance, including preliminary net product sales results for 2019, and key commercial and

  4. Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy

    SAN DIEGO and ALLSCHWIL, Switzerland, Jan. 10, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Idorsia Ltd. (SIX: IDIA) announced an amendment to the agreement that was originally signed in 2019

  5. Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy

    Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsyIdorsia to receive $45 million upfront upon exercise of the

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2a trial ongoing.
Crinecerfont (NBI-74788)
Congenital Adrenal Hyperplasia (CAH) - children
Pivotal trial to be initiated mid-2020. Phase 2 data to be presented at at ENDO March 28–31, 2020.
Crinecerfont (NBI-74788)
Congenital Adrenal Hyperplasia (CAH) - adults
Approval for sNDA 80 mg capsules announced October 5, 2017.
INGREZZA
Tardive dyskinesia
PDUFA date April 26, 2020.
Opicapone
Parkinson's disease
Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.
INGREZZA - T-Force GOLD
Tourette syndrome - juvenile
Phase 2 data released January 18, 2017 did not meet primary endpoint.
INGREZZA
Tourette syndrome - adults
NDA filing announced August 5, 2019.
Elagolix
Uterine Fibroids
FDA approval announced July 24, 2018.
Elagolix
Endometriosis
Approved April 11, 2017.
INGREZZA
Tardive dyskinesia
Phase 2 trial ongoing. Evaluating next steps.
INGREZZA - T-Force PLATINUM
Tourette syndrome - pediatric
Phase 2 trial initiated 3Q 2019.
Elagolix
Polycystic ovary syndrome (PCOS)
Phase 3 data due 2021.
Valbenazine - KINECT-HD
Huntington's disease

Latest News

  1. Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results

    SAN DIEGO, Jan. 20, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it will report fourth quarter and year-end 2019 financial results after the Nasdaq market closes on Tuesday, Feb.

  2. Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2020 and Provides Corporate Update

    Xenon's Proprietary Programs Continue to Advance with Multiple Mid to Late Stage Clinical Trials Anticipated to be Underway in 2020 Xenon Eligible for Milestone Payments Based on the Advancement of Partnered

  3. Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones

    SAN DIEGO, Jan. 12, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today provided an update on its business performance, including preliminary net product sales results for 2019, and key commercial and

  4. Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy

    SAN DIEGO and ALLSCHWIL, Switzerland, Jan. 10, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Idorsia Ltd. (SIX: IDIA) announced an amendment to the agreement that was originally signed in 2019

  5. Neurocrine Biosciences and Idorsia amend option agreement to license novel treatment for rare pediatric epilepsy

    Neurocrine Biosciences owns option to exclusively license ACT-709478, a clinical stage selective T-type calcium channel blocker for the treatment of epilepsyIdorsia to receive $45 million upfront upon exercise of the

  6. Neurocrine Biosciences to Present at the 38th Annual J.P. Morgan Healthcare Conference Live Audio Webcast will be on January 13, 2020

    SAN DIEGO, Jan. 6, 2020 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will present at the 38th Annual J.P. Morgan Healthcare Conference at 11:30 a.m. Pacific Time (2:30 p.m. Eastern Time) on Monday, Jan. 13,

  7. Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

    Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the "Genetic Epilepsies – Updates in the Science and Diagnosis" Exhibit in Room 318-319 on Sunday, December 8th Pre-Clinical Work

  8. Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

    Neurocrine Biosciences Gains Rights to XEN901, a Clinical Stage Selective Nav1.6 Sodium Channel Inhibitor, Being Developed for the Treatment of Epilepsy Xenon Receives $50 Million Upfront and Up to $1.7 Billion in

  9. Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy

    SAN DIEGO and BURNABY, British Columbia, Dec. 2, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and Xenon Pharmaceuticals Inc. (NASDAQ:XENE) announced a license and collaboration agreement to develop

  10. Neurocrine Biosciences to Present at Evercore ISI 2nd Annual HealthCONx Conference

    SAN DIEGO, Nov. 26, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will present at the Evercore ISI 2nd Annual HealthCONx Conference at 8:45 a.m. Eastern Time on Tuesday, Dec. 3, 2019, in Boston. Kevin

  11. Neurocrine Biosciences Publishes Long-Term INGREZZA® (valbenazine) Data in the Journal of Clinical Psychopharmacology Demonstrating Once-Daily 40 mg and 80 mg Capsules Reduced Involuntary Movements in Adults with Tardive Dyskinesia

    SAN DIEGO, Nov. 12, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that the Journal of Clinical Psychopharmacology1 published long-term data from the KINECT 4 Phase III, open-label study

  12. Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

    SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences:

  13. Neurocrine Biosciences Reports Third Quarter 2019 Financial Results

    SAN DIEGO, Nov. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2019 and provided an update on the launch of

  14. Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results

    SAN DIEGO, Oct. 14, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced today that it will report third quarter financial results after the Nasdaq market closes on Monday, November 4, 2019.

  15. Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

    SAN DIEGO, Oct. 4, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA® (valbenazine)

  16. Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress

    SAN DIEGO, Oct. 1, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg INGREZZA® (valbenazine) in adults with

  17. Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer

    SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that David W. Boyer has joined the company's executive management team as Chief Corporate Affairs Officer. Boyer

  18. Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®

    SAN DIEGO, Sept.17, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first

  19. Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the appointment of Leslie V. Norwalk to its Board of Directors. Ms. Norwalk formerly served as Acting Administrator for

  20. Neurocrine Biosciences to Present at Upcoming Healthcare Conferences

    SAN DIEGO, Aug. 28, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that Neurocrine Biosciences management will present at the following investor conferences: Matt Abernethy, Chief